RJA
FLNA

Raymond James & Associates’s Filana Therapeutics FLNA Stock Holding History

Raymond James & Associates’s Portfolio FLNA Stock Details FLNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$2.02M Sell
68,671
-8,288
-11% -$191K ﹤0.01% 2215
2024
Q2 		$950K Buy
76,959
+912
+1% +$19.2K ﹤0.01% 2657
2024
Q1 		$1.54M Buy
76,047
+1,950
+3% +$44.9K ﹤0.01% 2326
2023
Q4 		$1.67M Buy
74,097
+565
+0.8% +$11.9K ﹤0.01% 2203
2023
Q3 		$1.22M Buy
73,532
+12,129
+20% +$240K ﹤0.01% 2331
2023
Q2 		$1.51M Sell
61,403
-3,261
-5% -$78.5K ﹤0.01% 2239
2023
Q1 		$1.56M Buy
64,664
+3,592
+6% +$99.5K ﹤0.01% 2187
2022
Q4 		$1.8M Buy
61,072
+2,386
+4% +$85.8K ﹤0.01% 2054
2022
Q3 		$2.45M Buy
58,686
+13,656
+30% +$369K ﹤0.01% 1842
2022
Q2 		$1.27M Sell
45,030
-8,577
-16% -$217K ﹤0.01% 2298
2022
Q1 		$1.99M Buy
53,607
+9,916
+23% +$420K ﹤0.01% 2134
2021
Q4 		$1.91M Buy
43,691
+5,604
+15% +$294K ﹤0.01% 2211
2021
Q3 		$2.36M Buy
38,087
+19,945
+110% +$1.66M ﹤0.01% 1985
2021
Q2 		$1.55M Sell
18,142
-2,489
-12% -$133K ﹤0.01% 2286
2021
Q1 		$927K Buy
+20,631
New +$811K ﹤0.01% 2566

Other funds holding FLNA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GCM
Gallacher Capital Management Lone Tree, Colorado $178M AUM 29.29% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
TI
Tidal Investments Milwaukee, Wisconsin $47.4B AUM 59.58% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Raymond James & Associates's FLNA Position: Q3 2024 in Review

Raymond James & Associates reduced its Filana Therapeutics (FLNA) stake by 11% in Q3 2024, selling an estimated $191K and leaving 68,671 shares worth $2.02M. The position accounts for ﹤0.01% of the portfolio, ranked #2215.

Raymond James & Associates first reported a position in FLNA in Q1 2021 and has held it in 15 quarters since. The position peaked at $2.45M in Q3 2022. 161 funds tracked by Wall St. Rank hold FLNA as of Q3 2024.

  • Raymond James & Associates held 68,671 shares of Filana Therapeutics worth $2.02M as of Q3 2024.
  • Raymond James & Associates sold 8,288 Filana Therapeutics shares in Q3 2024, an estimated $191K.
  • Filana Therapeutics made up ﹤0.01% of Raymond James & Associates's portfolio in Q3 2024, its #2215 holding.
  • Raymond James & Associates first reported a position in Filana Therapeutics in Q1 2021 and has held it in 15 quarters since.
  • Raymond James & Associates's Filana Therapeutics position peaked at $2.45M in Q3 2022.
  • 161 funds tracked by Wall St. Rank held Filana Therapeutics as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.